Imagine trying to lock a door, but the lock keeps changing shape; that is how malaria parasites hide from our immune system. This work creates a better 'key' by finding new targets on the parasite and testing them in a safe, controlled environment. It's like a flight simulator for vaccines, allowing researchers to see if a shot works before testing it in the real world.
Current P. vivax malaria vaccines lack sufficient efficacy and there are too few candidate antigens in clinical testing. This creates a gap in protecting 2.5 billion people at risk.
A safe parasite clone for human challenge models and a set of functional assays using transgenic parasite lines to test vaccine efficacy.
If you are a vaccine manufacturer dealing with low efficacy rates in tropical diseases — this project developed new antigens and GMP bio-manufacturing know-how that improves the production of high-efficacy candidates. This reduces the risk of failure in late-stage trials.
If you are a drug discovery firm dealing with a lack of validated targets for malaria — this project developed reverse vaccinology tools and functional assays that identify which antigens actually work. This accelerates the pipeline from discovery to clinical testing.
If you are a CRO dealing with the difficulty of testing malaria vaccines in the field — this project developed a safe parasite clone for controlled human malaria infection (CHMI) models. This allows for faster benchmarking of vaccine efficacy in a controlled setting.
Based on available project data, there is no information regarding the cost or pricing of the vaccine.
The project focuses on improving GMP bio-manufacturing know-how to ensure sustainable delivery platforms, suggesting a path toward industrial scaling.
Based on available project data, specific IP and licensing terms are not disclosed, though the project involves a consortium of 10 partners including industry.
The project runs from 2023-06-01 to 2028-05-31, focusing on early-phase clinical assessment and benchmarking before future field trials.
It aligns with the Malaria Vaccine Technology Roadmap to 2030, which targets 75% efficacy over two years for P. vivax.
The consortium is heavily research-driven, consisting of 10 partners across 8 countries. It is dominated by universities (5) and research institutes (3), with a low industry ratio of 10% (1 partner). This structure indicates the project is primarily focused on high-risk, high-reward scientific discovery and clinical validation rather than immediate commercial rollout.
Contact Stichting Radboud Universitair Medisch Centrum in the Netherlands
Contact SciTransfer to identify the specific industrial partner in the consortium for licensing opportunities.
